XTL Biopharmaceuticals names CEO

Rehovot-based XTL Biopharmaceuticals named Ron Bentsur as chief executive, ending an 11-month period without a CEO.

By YIGAL GRAYEFF
January 4, 2006 08:13
xtl logo 88

xtl logo 88. (photo credit: )

Rehovot-based XTL Biopharmaceuticals named Ron Bentsur as chief executive, ending an 11-month period without a CEO. In February, rebel investors persuaded shareholders to oust interim chairman and chief executive Elkan Gamzu and two other directors. XTL appointed Michael Weiss as interim chairman in March and then non-executive chairman in August, but failed to appoint a CEO until now. XTL said on Tuesday that Bentsur comes from US company Keryx Biopharmaceuticals, where he is vice president for finance and investor relations, a job he will continue to carry out for a transitional period.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS

Israel Weather
  • 9 - 19
    Beer Sheva
    11 - 18
    Tel Aviv - Yafo
  • 8 - 16
    Jerusalem
    12 - 18
    Haifa
  • 12 - 25
    Elat
    12 - 22
    Tiberias